FDA warns about dental problems with buprenorphine medicines

The U.S. Food and Drug Administration (FDA) is warning that dental problems have been reported with medicines containing buprenorphine that dissolve in the mouth. The dental problems include tooth decay, cavities, oral infections, and tooth loss. This can be serious and has been reported in patients with no history of dental issues. Despite these risks, buprenorphine is an important treatment option for opioid use disorder (OUD) and pain. We ask our providers to take this information into account when prescribing buprenorphine medicines to our members.

 

Please refer to the FDA Drug Safety Communication to review the full notice.

Email is the quickest and most direct way to receive important information from Anthem Blue Cross. 
To start receiving email from us (including some sent in lieu of fax or mail), submit your information using the QR code to the right or via our online form (https://bit.ly/3lLgko8).

ACA-NU-0416-22